Back to results
US 2012/0238628 A1Published application
Dihydronaphthalene and naphthalene derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
AssigneeAllergan, Inc.
InventorsVidyasagar Vuligonda, Richard L. Beard, Thong Vu, John E. Donello, Veena Viswanath, Michael E. Garst
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
Claims13
A compound having Formula I, its enantiomers, diastereoisomers, regio isomers, hydrates, solvates, crystal forms and individual isomers, tautomers or a pharmaceutically acceptable salt thereof,
- wherein:
- “” is a single bond or a double bond;
- “” is a single bond or a double bond;
- R1 is H, halogen, —S(O)R10, —S(O)2R11, nitro, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl or hydroxyl;
- R2 is H, halogen, —S(O)R10, —S(O)2R11, nitro, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl or hydroxyl;
- R3 is H, halogen, —S(O)R10, —S(O)2R11, nitro, cyano, —OC1-6 alkyl, —SO1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl, C6-10 aryl or hydroxyl;
- R4 is H or C(O)R12;
- R5 is H, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl or —C2-6 alkynyl;
- R6 is H, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl or —C2-6 alkynyl;
- Y is O or S;
- X is O, NR, or CH2;
- Ra is C6-10 aryl,
- heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl or H;
- Rb is halogen;
- c is 0, 1 or 2;
- R7 is H, halogen, —S(O)R16, —S(O)2R11, nitro, hydroxyl, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- R8 is H, halogen, —S(O)R10, —S(O)2R11, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- R9 is H, —S(O)2R11, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- R10 is —C1-6 alkyl, C3-8 cycloalkyl, or C3-8 cycloalkenyl;
- R11 is H, hydroxyl, —C1-6 alkyl, C3-8 cycloalkyl or C3-8 cycloalkenyl;
- R12 is H, hydroxyl, —C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, NR13R14 or —OC1-6 alkyl;
- R13 is H, —C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl SO2R11 or C(O)R15;
- R14 is H, —C1-6 alkyl, C3-8 cycloalkenyl, aryl, heterocycle or C3-8 cycloalkyl;
- R15 is H, —C1-6 alkyl, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- and
- R is H, —C1-6 alkyl, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- with the provisos
- when “” is a double bond then R5 and R6 are void;
- and
- the compound is not of structures
27 more elements
A method of treating a disorder associated with N-formyl peptide receptor like-1 (FPRL-1) receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
- wherein:
- “” is a single bond or a double bond;
- “” is a single bond or a double bond;
- R1 is H, halogen, —S(O)R10, —S(O)2R11, nitro, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl or hydroxyl;
- R2 is H, halogen, —S(O)R10, —S(O)2R11, nitro, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl or hydroxyl;
- R3 is H, halogen, —S(O)R10, —S(O)2R11, nitro, cyano, —OC1-6 alkyl, —SO1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl, C6-10 aryl or hydroxyl;
- R4 is H or C(O)R12;
- R5 is H, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl or —C2-6 alkynyl;
- R6 is H, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl or —C2-6 alkynyl;
- Y is O or S;
- X is O, NR, or CH2;
- Ra is C6-10 aryl,
- heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl or H;
- Rb is halogen;
- c is 0, 1 or 2;
- R7 is H, halogen, —S(O)R10, —S(O)2R11, nitro, hydroxyl, cyano, —OC1-6 alkyl, —SO1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- R8 is H, halogen, —S(O)R10, —S(O)2R11, cyano, —OC1-6 alkyl, —SC1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, NR13R14, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- R9 is H, —S(O)2R11, —OC1-6 alkyl, —SO1-6 alkyl, —C1-6 alkyl, —C2-6 alkenyl, —C2-6 alkynyl, C(O)R12, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- R10 is —C1-6 alkyl, C3-8 cycloalkyl, or C3-8 cycloalkenyl;
- R11 is H, hydroxyl, —C1-6 alkyl, C3-8 cycloalkyl or C3-8 cycloalkenyl;
- R12 is H, hydroxyl, —C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, NR13R14 or —OC1-6 alkyl;
- R13 is H, —C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl SO2R11 or C(O)R15;
- R14 is H, —C1-6 alkyl, C3-8 cycloalkenyl, aryl, heterocycle or C3-8 cycloalkyl;
- R15 is H, —C1-6 alkyl, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- and
- R is H, —C1-6 alkyl, C3-8 cycloalkenyl or C3-8 cycloalkyl;
- with the provisos
- when “” is a double bond then R5 and R6 are void;
- and
- the compound is not of structures
27 more elements
Dependencies are inferred from the claim text.